EGFR and neoplasm: This proved to bea promising strategy for improving therapeutic cargo on GBM cells,as the binding of CTX-NPs with MMP-2 reduced its catalytic activityby 50%.179 Furthermore, Erel-Akbaba et al. developed SLNs functionalized with cyclic iRGD peptidefor a combined gene delivery immunotherapy against EGFR and programmedcell death ligand-1 (PD-L1), both contributing to tumor developmentand proliferation.